Summary by Moomoo AI
Incannex Healthcare Inc., a biopharmaceutical company, reported its financial results for the quarter ended December 31, 2023. The company's cash and cash equivalents stood at $14.554 million, a decrease from the previous period's $22.120 million. Total current assets were $21.332 million, while total assets amounted to $22.359 million. The company's liabilities totaled $3.487 million, with stockholders' equity at $18.872 million. Research and development expenses increased to $2.638 million, up from $1.549 million in the same period last year, reflecting the company's investment in clinical trials and product development. General and administrative expenses also rose to $5.345 million, driven by higher employee benefits and legal costs associated with the company's re-domiciliation. The company reported a net loss of $5.241 million, compared to a net loss of $2.918 million...Show More